Abstract
Atopic dermatitis is a chronic, recurrent inflammatory skin disorder manifesting by eczematous lesions and intense pruritus. Atopic dermatitis develops primarily as a result of an epidermal barrier defect and immunological imbalance. Advances in understanding these pathogenetic hallmarks, and particularly the complex role of interleukins as atopic dermatitis drivers, resulted in achieving significant therapeutic breakthroughs. Novel medications involve monoclonal antibodies specifically blocking the function of selected interleukins and small molecules such as Janus kinase inhibitors limiting downstream signaling to reduce the expression of a wider array of proinflammatory factors. Nevertheless, a subset of patients remains refractory to those treatments, highlighting the complexity of atopic dermatitis immunopathogenesis in different populations. In this review, we address the immunological heterogeneity of atopic dermatitis endotypes and phenotypes and present novel interleukin-oriented therapies for this disease.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference165 articles.
1. The burden of atopic dermatitis: Impact on the patient, family, and society;Carroll;Pediatr. Dermatol.,2005
2. Atopic dermatitis;Langan;Lancet Lond. Engl.,2020
3. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association;Drucker;J. Investig. Dermatol.,2017
4. Atopic dermatitis: An expanding therapeutic pipeline for a complex disease;Bieber;Nat. Rev. Drug Discov.,2022
5. Sroka-Tomaszewska, J., and Trzeciak, M. (2021). Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int. J. Mol. Sci., 22.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献